Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

University of Florida, said, "Chronic hepatitis C represents a significant unmet medical need. These Phase 3 results suggest that albinterferon alfa-2b has the potential to become an important new treatment option for patients with chronic hepatitis C. Albuferon requires half as many injections as the pegylated interferons, and clinical results to date suggest that it may offer comparable efficacy, with no difference in clinically significant adverse events. The observed variation in response by geography is an unexpected finding and requires further analysis. We look forward to results from the ACHIEVE 1 trial, which is evaluating albinterferon alfa-2b in the treatment of patients with genotype 1 hepatitis C."

In the randomized, multi-center, active-controlled non-inferiority Phase 3 trial, 933 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C were initially assigned to one of three treatment groups, including two groups that received albinterferon alfa-2b once every two weeks at doses of 900-mcg or 1200-mcg, and an active control group that received peginterferon alfa-2a once weekly at a dose of 180-mcg - with all patients receiving oral ribavirin daily at 800-mg in two divided doses. In January 2008, a dose modification was made and patients originally assigned to receive the 1200-mcg dose of albinterferon alfa-2b had their dose reduced to 900-mcg albinterferon alfa-2b every two weeks. The dose modification was recommended by the independent Data Monitoring Committee (DMC) for the Albuferon Phase 3 trials, following their observation during a routine review of unblinded data from both trials that serious pulmonary adverse events were higher in the 1200-mcg Albuferon treatment group. Following the dose modification, the study continued to follow all patients randomized into the trial on an intention-to-treat (ITT) basis according to their original dose assignment. The primary data analysis compares the
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Genome Sciences at the University of Maryland School of ... Medical Research Institute of Infectious Diseases and Northern Arizona ... their investigation into the anthrax attacks of 2001. The ... microbiology in a criminal investigation. More than 20 people ...
... package designed to minimize the potential risks of synthetic ... available to the gene synthesis industry and synthetic biology ... licensed GenoTHREAT, a software tool that helps detect the ... an open-source project by a team led by Jean ...
... new drug that will regenerate a critical enzyme in ... exposed to deadly chemical warfare agents. Christopher Hadad, ... (OSU), is leveraging Ohio Supercomputer Center (OSC) resources to ... called organophosphorus (OP) nerve agents. "This project ...
Cached Biology Technology:University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4Open-source software designed to minimize synthetic biology risks 2OSU chemist developing solution to nerve agent exposure 2
(Date:4/21/2014)... daily pill to lower cholesterol can reduce heart attack ... inflammation could help save the vision of diabetics, scientists ... with high doses of niacin to decrease bad cholesterol ... an effective mark for these patients, said Dr. Pamela ... Georgia Regents University. , Martin is Principal Investigator ...
(Date:4/21/2014)... In recent years, there are growing studies ... for sustained-release and controlled-release of nerve growth ... by Prof. Gao Li and team from ... and Technology in China, amino-functionalized ethylenediamine-treated multi-walled ... nanotubes-nerve growth factor complexes by non-covalent grafting. ...
(Date:4/20/2014)... to treat lung, breast and pancreatic cancers also promote ... University of California, San Diego School of Medicine have ... surface of drug-resistant tumors that appears responsible for inducing ... cancer cells. , The findings, published in the ... Biology , may point to new therapeutic opportunities for ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Cancer stem cells linked to drug resistance 2
... Jewish Health have discovered a type of cell that may ... lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently ... make autoantibodies, which bind to and attack the body,s own ... of the journal Blood , that they found higher ...
... programmed cell death - a process by which cells ... in termites. And it appears this regression may be ... defensive organs, according to Kouhei Toga and Kiyoto Maekawa ... the University of Tokyo, in Japan. Their findings have ...
... tropics make it tough for farmers to keep their crops ... seems to defy efforts to control its population. Some farmers ... the weevils but they have not been successful. Since the ... the immature stages. The sweetpotato weevil is a year round ...
Cached Biology News:B-cell discovery suggests why women suffer more autoimmune disease 2Cells die so defensive organs can live 2Biocontrol of sweetpotato weevils 2
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: